Suchergebnisse - "Chakladar, Sujatro"

PubPharm (11)

1

Tirzepatide for the treatment of obstructive sleep apnea : Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial

enthalten in: Contemporary clinical trials | 2024

von Malhotra, A. | Bednarik, J. | Chakladar, S. | +9

2

Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial

enthalten in: bioRxiv.org | 2023

von Marconi, V. | Ramanan, A. | de Bono, S. | +16

3

Estimands, Handling of Missing Data and Impact on Assumed Effect Size and Power in Pivotal COVID-19 Treatment Trials

enthalten in: Journal of biopharmaceutical statistics | 2023

von Chakladar, S. | Liao, R. | Gamalo, M.

4

Win ratio approach for analyzing composite time-to-event endpoint with opposite treatment effects in its components

enthalten in: Pharmaceutical statistics | 2022

von Liao, R. | Chakladar, S. | Gamalo, M.

5

Inverse probability weighted estimators of vaccine effects accommodating partial interference and censoring

enthalten in: Biometrics | 2022

von Chakladar, S. | Rosin, S. | Hudgens, M. | +4

6

Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation : an exploratory, randomised, placebo-controlled trial

enthalten in: The Lancet. Respiratory medicine | 2022

von Ely, E. | Ramanan, A. | Kartman, C. | +25

CommentIn: Lancet Respir Med. 2022 Apr;10(4):314-315. - PMID 35123659

7

Inverse probability weighted estimators of vaccine effects accommodating partial interference and censoring

enthalten in: Biometrics | 2022

von Chakladar, S. | Rosin, S. | Hudgens, M. | +4

8

Win ratio approach for analyzing composite time‐to‐event endpoint with opposite treatment effects in its components

enthalten in: Pharmaceutical Statistics | 2022

von Liao, R. | Chakladar, S. | Gamalo, M.

9

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER) : a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

enthalten in: The Lancet. Respiratory medicine | 2021

von Marconi, V. | Ramanan, A. | de Bono, S. | +105

CommentIn: Lancet Respir Med. 2021 Dec;9(12):1349-1351. - PMID 34480862

10

Baricitinib plus Standard of Care for Hospitalised Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomised, Placebo-Controlled Trial

enthalten in: bioRxiv.org | 2021

von Ely, E. | Ramanan, A. | Kartman, C. | +7